Osimertinib induction and maintenance for chemo-ineligible Stage III unresectable EGFR+ NSCLC: single-arm study

Trial Identifier: D5167L00001
Sponsor: AstraZeneca
Start Date: March 2026
Primary Completion Date: May 2029
Study Completion Date: May 2029
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100021
CN Beijing, CN, 100730
CN Changchun, CN, 130021
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN Foshan, CN, 528000
CN fuzhou, CN, 350011
CN Guangzhou, CN, 510060
CN Guangzhou, CN, 510100
CN Harbin, CN, 150081
CN Hefei, CN, 230031
CN Jinan, CN, 250021
CN Kunming, CN, 650118
CN Nanchang, CN, 330006
CN Qingdao, CN, 110016
CN Shanghai, CN, 200433
CN Shanghai, CN, 200120
CN Taiyuan, CN, 030000
CN Wenzhou, CN, 325000
CN Xuzhou, CN, 221000